Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ Randomized Clinical Trial.

17 We do not see associations between change in iADRS and change in plasma pTau 217 or GFAP, except a borderline significant association between plasma pTau 217 change at 24 weeks with the marginal odds of exhibiting a meaningful worsening (MCID) on iADRS.

also in 11,409 other papers

A second consideration relevant to the present finding is that we do not presently know the time lag between onset of Aβ pathology and downstream neurodegeneration, but it may be significant.

also in 13,097 other papers